{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:48:27Z","timestamp":1792612107226,"version":"4.5.0"},"reference-count":50,"publisher":"Hindawi Limited","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":26,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1111\/ijcp.12714","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T15:42:57Z","timestamp":1438875777000},"page":"978-997","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel"],"prefix":"10.1155","volume":"69","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College; Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"key":"10.1111\/ijcp.12714-BIB0001|ijcp12714-cit-0001","unstructured":"Otsuka REXULTI (brexpiprazole) tablets, for oral use 2015 http:\/\/www.otsuka-us.com\/products\/Documents\/Rexulti.PI.pdf"},{"key":"10.1111\/ijcp.12714-BIB0002|ijcp12714-cit-0002","unstructured":"Otsuka, Lundbeck U.S. FDA Approves Otsuka and Lundbeck's REXULTI (Brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with Schizophrenia 2015 http:\/\/www.otsuka-us.com\/newsroom\/Pages\/NewsArticle.aspx?ItemId=13"},{"key":"10.1111\/ijcp.12714-BIB0003|ijcp12714-cit-0003","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1358\/dot.2015.51.7.2358605","article-title":"Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder","volume":"51","author":"Citrome","year":"2015","journal-title":"Drugs Today (Barc)"},{"key":"10.1111\/ijcp.12714-BIB0004|ijcp12714-cit-0004","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1517\/14656560903061309","article-title":"Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making","volume":"10","author":"Volavka","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"July","key":"10.1111\/ijcp.12714-BIB0005|ijcp12714-cit-0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1111\/ijcp.12714-BIB0006|ijcp12714-cit-0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in\u00a0vitro and in\u00a0vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ijcp.12714-BIB0007|ijcp12714-cit-0007","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.euroneuro.2014.12.014","article-title":"Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator","volume":"25","author":"Yoshimi","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12714-BIB0008|ijcp12714-cit-0008","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/jpet.114.218578","article-title":"Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in\u00a0vivo electrophysiologic characterization","volume":"351","author":"Oosterhof","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ijcp.12714-BIB0009|ijcp12714-cit-0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pbb.2014.06.008","article-title":"Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors","volume":"124","author":"Yoshimi","year":"2014","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1111\/ijcp.12714-BIB0010|ijcp12714-cit-0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1124\/jpet.114.213819","article-title":"Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ijcp.12714-BIB0011|ijcp12714-cit-0011","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euroneuro.2015.01.014","article-title":"Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors","volume":"25","author":"Ishima","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12714-BIB0012|ijcp12714-cit-0012","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial","author":"Correll","year":"2015","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12714-BIB0013|ijcp12714-cit-0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","author":"Kane","year":"2015","journal-title":"Schizophr Res"},{"issue":"9 Suppl. 1","key":"10.1111\/ijcp.12714-BIB0014|ijcp12714-cit-0014","first-page":"203S","article-title":"The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study","volume":"77","author":"Citrome","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"9 Suppl. 1","key":"10.1111\/ijcp.12714-BIB0015|ijcp12714-cit-0015","first-page":"66S","article-title":"Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study","volume":"77","author":"Davis","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"9 Suppl. 1","key":"10.1111\/ijcp.12714-BIB0016|ijcp12714-cit-0016","first-page":"65S","article-title":"Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and irritability: an exploratory study","volume":"77","author":"Menard","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"9 Suppl. 1","key":"10.1111\/ijcp.12714-BIB0017|ijcp12714-cit-0017","first-page":"64S","article-title":"Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study","volume":"77","author":"Krystal","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12714-BIB0018|ijcp12714-cit-0018","first-page":"S333","article-title":"Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies","volume":"41","author":"Skuban","year":"2015","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12714-BIB0019|ijcp12714-cit-0019","first-page":"S309","article-title":"Analysis of efficacy and metabolic tolerability profile from two phase 3 studies of brexpiprazole in patients with acute schizophrenia","volume":"41","author":"Duffy","year":"2015","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12714-BIB0020|ijcp12714-cit-0020","first-page":"S307","article-title":"Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies","volume":"41","author":"Correll","year":"2015","journal-title":"Schizophr Bull"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12714-BIB0021|ijcp12714-cit-0021","first-page":"S357","article-title":"Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies","volume":"39","author":"Thase","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/ijcp.12714-BIB0022|ijcp12714-cit-0022","unstructured":"Thase ME Augustine C Carson WH Adjunctive brexpiprazole (OPC-34712) in major depressive disorder (MDD): efficacy over a range of outcomes"},{"key":"10.1111\/ijcp.12714-BIB0023|ijcp12714-cit-0023","unstructured":"McIntyre RS Zhang P Weiss C Weiller E Effect of adjunctive brexpiprazole (OPC-34712) on depressive symptoms in patients with symptoms of anxious distress: results from post-hoc analyses"},{"key":"10.1111\/ijcp.12714-BIB0024|ijcp12714-cit-0024","unstructured":"Nelson JC Skuban A Zhang P Weiller E Weiss C Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies"},{"key":"10.1111\/ijcp.12714-BIB0025|ijcp12714-cit-0025","unstructured":"Marder SR Skuban A Ouyang J Weiss C Weiller E Efficacy of brexpiprazole (OPC-34712) on PANSS items and Marder Factor scores: a meta-analysis of two pivotal studies in schizophrenia"},{"key":"10.1111\/ijcp.12714-BIB0026|ijcp12714-cit-0026","unstructured":"Eramo A Skuban A Ouyang J Hobart M Weiss C Weiller E Incidence, onset, duration and severity of akathisia with brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies"},{"key":"10.1111\/ijcp.12714-BIB0027|ijcp12714-cit-0027","unstructured":"Weiss C Skuban A Hobart M Zhang P Weiller E Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (OPC-34712) in major depressive disorder: analysis of two pivotal studies"},{"key":"10.1111\/ijcp.12714-BIB0028|ijcp12714-cit-0028","unstructured":"Fava M Weiller E Zhang P Weiss C The effect of adjunctive brexpiprazole (OPC-34712) on depressive symptoms in patients with irritability: results from post-hoc analyses"},{"key":"10.1111\/ijcp.12714-BIB0029|ijcp12714-cit-0029","unstructured":"Hobart M Ouyang J Forbes A Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study"},{"key":"10.1111\/ijcp.12714-BIB0030|ijcp12714-cit-0030","unstructured":"Malla A Sugaya K Perry P Nagamizu K Weiller E Baker RA The effect of brexpiprazole (OPC-34712) in adult outpatients with early-episode schizophrenia: an exploratory study"},{"key":"10.1111\/ijcp.12714-BIB0031|ijcp12714-cit-0031","unstructured":"Weiss C Skuban A Hobart M Zhang P Weiller E The metabolic tolerability profile of brexpiprazole (OPC-34712) in acute schizophrenia"},{"key":"10.1111\/ijcp.12714-BIB0032|ijcp12714-cit-0032","unstructured":"Nelson JC Skuban A Hobart M Zhang P Weiss C Weiller E The metabolic tolerability profile of adjunct brexpiprazole (OPC-34712) in major depressive disorder"},{"key":"10.1111\/ijcp.12714-BIB0033|ijcp12714-cit-0033","unstructured":"Trivedi M Weiller E Okame T Perry P Matsushima Y Baker RA Switching from inadequate adjunctive treatment options to brexpiprazole adjunctive to antidepressant: an open-label study on the effects on depressive symptoms and cognitive and physical functioning"},{"key":"10.1111\/ijcp.12714-BIB0034|ijcp12714-cit-0034","unstructured":"Weisler R Ota A Perry P Adjunctive brexpiprazole (OPC-34712) in young patients with MDD who are working or at school: an exploratory study"},{"key":"10.1111\/ijcp.12714-BIB0035|ijcp12714-cit-0035","unstructured":"McQuade R Hobart M Forbes RA A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203)"},{"key":"10.1111\/ijcp.12714-BIB0036|ijcp12714-cit-0036","unstructured":"Thase M Fava M Hobart M Efficacy and safety of adjunctive OPC-34712 in major depressive disorder: a phase II, randomized, placebo-controlled study"},{"key":"10.1111\/ijcp.12714-BIB0037|ijcp12714-cit-0037","unstructured":"Thase ME Hobart M Augustine C Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder (MDD): a phase 3, randomized, placebo-controlled study"},{"key":"10.1111\/ijcp.12714-BIB0038|ijcp12714-cit-0038","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12714-BIB0039|ijcp12714-cit-0039","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12714-BIB0040|ijcp12714-cit-0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12714-BIB0041|ijcp12714-cit-0041","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","article-title":"On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not","volume":"13","author":"Citrome","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/ijcp.12714-BIB0042|ijcp12714-cit-0042","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"J Expert Rev Neurother"},{"key":"10.1111\/ijcp.12714-BIB0043|ijcp12714-cit-0043","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/ijcp.12714-BIB0044|ijcp12714-cit-0044","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2174\/1574886309666140601211551","article-title":"Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychotics","volume":"9","author":"Citrome","year":"2014","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12714-BIB0045|ijcp12714-cit-0045","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-013-0105-7","article-title":"A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach","volume":"27","author":"Citrome","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12714-BIB0046|ijcp12714-cit-0046","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","author":"Citrome","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1111\/ijcp.12714-BIB0047|ijcp12714-cit-0047","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/01.pra.0000271657.09717.e2","article-title":"Intramuscular aripiprazole in the control of agitation","volume":"13","author":"Currier","year":"2007","journal-title":"J Psychiatr Pract"},{"key":"10.1111\/ijcp.12714-BIB0048|ijcp12714-cit-0048","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/14737175.2013.811984","article-title":"New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia","volume":"13","author":"Citrome","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/ijcp.12714-BIB0049|ijcp12714-cit-0049","first-page":"42","article-title":"Beyond PubMed: searching the \u201cGrey Literature\u201d for clinical trial results","volume":"11","author":"Citrome","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1111\/ijcp.12714-BIB0050|ijcp12714-cit-0050","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1742-1241.2010.02344.x","article-title":"Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic","volume":"64","author":"Citrome","year":"2010","journal-title":"Int J Clin Pract"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12714","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:16Z","timestamp":1643349856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,6]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12714","archive":["Portico"],"relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8,6]]}}}